A chance to end an epidemic. How are pharmaceutical companies improving access to hepatitis C treatment?

From 2011, a new generation of hepatitis C drugs began to enter the market, revolutionising treatment. In 2015, six of these drugs were added to the WHO Essential Medicines List. The Access to Medicine Foundation has produced the first overview of how pharmaceutical companies are working to make these drugs available, accessible and affordable to the global poor. Company engagement is a key factor in controlling the global hepatitis epidemic.

Published in the Bulletin of the World Health Organization, and reproduced here with supplementary information about company activities, the study finds that these companies can engage more broadly and more deeply in global efforts to end the epidemic. Companies are strongly encouraged to:

- Make greater efforts to improve the affordability of treatments for hepatitis C;
- Support the entry of generic medicine manufacturers into the hepatitis C space in order to ensure supply and affordability;
- Consider access strategies early on in the process of developing promising new drugs.
Table of contents

3 Executive Summary

7 Access to hepatitis C medicines

7 Introduction
   • Hepatitis C medicines
   • Current treatment
   • New treatment options
   • Access to medicine strategies

10 Discussion
   • Affordability
   • Generic partners
   • Plan access strategies early
   • Supporting awareness and diagnosis

11 Conclusion

13 References

14 Overview of access strategies reported by the pharmaceutical industry for hepatitis C products
   This information is supplementary to the paper as published in the Bulletin of the World Health Organization on 1 November, 2015.

18 Appendix: About the Access to Medicine Index
   All references are included on pp. 13, as part of the paper published in the Bulletin of the World Health Organization.

About the Access to Medicine Foundation
This analysis examines data from the 2014 Access to Medicine Index, supplemented with more recent publicly available data from company press releases and other sources. The Access to Medicine Index is published by the Access to Medicine Foundation, a non-profit organisation based in the Netherlands that aims to advance access to medicine by encouraging the pharmaceutical industry to play a greater role in improving access to medicine in less developed countries. The Index methodology was developed, and is continually refined, in consultation with multiple stakeholders including the World Health Organization, NGOs, governments, universities and institutional investors.

The Access to Medicine Foundation is funded by the Bill & Melinda Gates Foundation, the Dutch Ministry of Foreign Affairs, and the UK Department for International Development. The Access to Medicine Foundation is now developing a second Index of healthcare companies, the Access to Vaccines Index, with funding from the Dutch National Postcode Lottery. www.atmindex.org
Executive Summary

New treatments offer the chance to curb the global hepatitis C epidemic. The companies responsible for innovating and producing these drugs can play a central role in achieving this important goal. The Access to Medicine Foundation recommends that companies make greater efforts to improve the affordability of these drugs, support the entry of generic medicine manufacturers to ensure supply and affordability, and implement access strategies early in the development of promising drugs.

An estimated 185 million people globally are infected with the hepatitis C virus, with 350,000–500,000 people dying of this disease each year. The vast majority (80%) of those affected by hepatitis C live in low- and middle-income countries.

From 2011, a new generation of hepatitis C drugs began to enter the market, revolutionising treatment through simpler administration, higher cure rates and shorter course durations than previous therapies. These drugs represent a real possibility for controlling the epidemic, and an effective cure. In May 2015, the World Health Organization (WHO) responded by adding six of these drugs to the WHO Essential Medicines List. This sent a clear signal about their importance and the need for them to be made available. For donors and countries to engage in the provision of these treatments effectively, the drugs need to be affordable and supply needs to be secured. What are pharmaceutical companies doing to help ensure that these goals are achieved?

In a study published on 1 November 2015 in the Bulletin of the World Health Organization, we have examined the pipelines and on-market products for hepatitis C of 20 of the world’s largest pharmaceutical companies, as well as their strategies for supporting access to these treatments in 107 low- and middle-income countries. The study represents the first overview of access-to-medicine activities being undertaken by these companies in the hepatitis C space.

This report includes the full text of the study as published in the Bulletin (see pp 7-13), as well as supplementary information on a company-by-company, product-by-product basis about the access strategies deployed by the companies examined (see pp 14-16).
Findings

Products and pipelines
Six of the world's largest pharmaceutical companies are marketing medicines for hepatitis C. Five are marketing the new generation of medicines (AbbVie, Bristol-Myers Squibb, Gilead, Johnson & Johnson and Merck & Co.). In addition, Merck & Co. and Roche are marketing older, first-generation treatments. Products from AbbVie, Bristol-Myers Squibb, Gilead and Johnson & Johnson have recently been added to the WHO Essential Medicines List. There is evidence that access strategies are in place for two of the newer hepatitis C products: Sovaldi® (sofosbuvir) and ledipasvir (both Gilead).

Looking at the pipeline of hepatitis C drugs, these same six companies are developing almost 30 new treatments in total, eleven of which are in Phase 3, and closest to reaching the market. Hepatitis C drug development is a crowded, competitive space, with some companies withdrawing products from specific markets (Merck & Co., Vertex) and others disengaging from hepatitis C drug development (Boehringer-Ingelheim).

Figure 1. Clinical trial stages of hepatitis C medicines, 2015

<table>
<thead>
<tr>
<th>Company</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>0</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Gilead</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Merck &amp; Co.</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Roche</td>
<td>1</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

Pricing and licensing strategies
In the Bulletin article, we prioritised two approaches companies can take to address access to hepatitis C medicines. These are affordability, and the facilitation of generic market entry.

Three companies have differential pricing strategies for hepatitis C products (Gilead, Merck & Co. and Roche). Gilead markets Sovaldi® (sofosbuvir) and Harvoni® (sofosbuvir/ledipasvir), both new additions to the WHO Essential Medicines List. Gilead initially charged US$84,000 for a course of Sovaldi® (sofosbuvir) in the United States. At the time of analysis, the lowest identified price for a course of that treatment in a developing country was US$900 (US$300 per bottle) and US$400 per bottle for Harvoni® (sofosbuvir/ledipasvir). While Gilead's discounts here are clearly large, a discount against developed country prices does not in itself guarantee affordability. Gilead did not provide evidence that it took the affordability of these products into account when setting these price points.

Only Gilead is currently actively licensing products for hepatitis C to generic manufacturers. The scopes of the licences agreed are broad and include both Sovaldi® (sofosbuvir) and Harvoni® (sofosbuvir/ledipasvir), yet they do not include key middle-income country markets.
with high hepatitis C burdens, such as Brazil, China, Georgia, Mexico, Thailand and Ukraine. Gilead is also the only company to have pro-actively licensed hepatitis C medicines before the products were registered (ledipasvir and velpatasvir).

In late 2014, Bristol-Myers Squibb announced an intention to engage in both differential pricing and licensing for hepatitis C products. In the second half of 2015, it adjusted the publicly disclosed geographic scope of these proposed agreements (from 90 to 112 countries) and confirmed that the licences would be royalty-free.

Of the four companies marketing the newer hepatitis C treatments on the WHO Essential Medicines List, Gilead has the most wide-ranging and tailored approach for improving accessibility. However, as noted above, its approach has limitations in geographic scope, and how it considers affordability is unclear. Bristol-Myers Squibb has made an important step in setting out its planned hepatitis C access strategy, but needs to transform its commitment into practice. Neither AbbVie nor Johnson & Johnson have yet disclosed evidence regarding how they intend to support low and middle-income country governments and donors in making the essential medicines they market available and accessible.

**Recommendations**

**Companies can engage more broadly and more deeply in global efforts to end the epidemic**

While companies’ existing activities are welcomed, greater engagement and effort from companies that hold patents in this space are needed in order to ensure a secure supply of essential innovative drugs for treating hepatitis C is made available to the global poor at truly affordable prices. The Access to Medicine Foundation calls on pharmaceutical companies active in hepatitis C to:

- **Prioritise rigorous assessments of affordability when setting prices**, paying attention to ability to pay rather than willingness to pay. Setting lower prices for countries on the basis of income alone is not sufficient. Affordable prices will encourage greater donor and government investment to purchase medicines at the scale necessary. Further, patient-level affordability considerations are particularly important where people pay for drugs out of their own pockets.

- **Make use of the manufacturing capacity and quality of partners in the generic medicine industry through licensing** in order to scale up production, secure supply, and improve affordability. The positive impact of competition from generic medicine manufacturers on prices has been amply demonstrated in the context of HIV/AIDS treatments over recent years (the average price of a first-line adult antiretroviral regimen dropped from US$414 per person per year in 2003 to US$74 in 2008). Licensing arrangements should be transparent, and the terms they contain should be as flexible as possible, allowing generic medicine manufacturers to produce in the most cost-effective manner.

- **Consider access strategies (both within and beyond the management of intellectual property) or pipeline drugs as soon as they have a substantial chance of getting to the market** (typically in later clinical trial stages), to ensure companies are well-positioned to promptly introduce products to lower-income markets. It is important for those in need everywhere to rapidly have access to innovative treatments.
Access to hepatitis C medicines
Danny J. Edwards et al


Contents

7 Introduction
- Hepatitis C medicines
- Current treatment
- New treatment options
- Access to medicine strategies

10 Discussion
- Affordability
- Generic partners
- Plan access strategies early
- Supporting awareness and diagnosis

11 Conclusion

13 References


© 2015 Danny J Edwards, Delphi GM Coppens, Tara L Prasad, Laurien A Rook, Jayasree K Iyer; licensee the World Health Organization. This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL."
Access to hepatitis C medicines

Abstract
Hepatitis C is a global epidemic. Worldwide, 185 million people are estimated to be infected, most of whom live in low- and middle-income countries. Recent advances in the development of antiviral drugs have produced therapies that are more effective, safer and better tolerated than existing treatments for the disease. These therapies present an opportunity to curb the epidemic, provided that they are affordable, that generic production of these medicines is scaled up and that awareness and screening programmes are strengthened. Pharmaceutical companies have a central role to play. We examined the marketed products, pipelines and access to medicine strategies of 20 of the world’s largest pharmaceutical companies. Six of these companies are developing medicines for hepatitis C: AbbVie, Bristol-Myers Squibb, Gilead, Johnson & Johnson, Merck & Co. and Roche. These companies employ a range of approaches to supporting hepatitis C treatment, including pricing strategies, voluntary licensing, capacity building and drug donations. We give an overview of the engagement of these companies in addressing access to hepatitis C products. We suggest actions companies can take to play a greater role in curbing this epidemic: (i) prioritizing affordability assessments; (ii) developing access strategies early in the product lifecycle; and (iii) licensing to manufacturers of generic medicines.

Introduction
Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV). There is a global epidemic of hepatitis C, with approximately 185 million people estimated to be infected in 2005 and 350,000–500,000 deaths estimated annually. Over 80% of those affected by the disease live in low- and middle-income countries, especially in central, north and west Africa. Several middle-income countries such as Egypt, Nigeria and Pakistan have a high burden of hepatitis C.

HCV is most often spread when infected blood enters the body. High-risk populations include intravenous drug-users and recipients of blood transfusions in poorly controlled environments; but the virus is also found in the general population. There are six genotypes of HCV, with distributions varying by region. It is possible for a person to be infected with multiple genotypes; 55–85% of people will develop chronic infection and about one third of these, if not treated, will eventually develop liver cirrhosis or hepatocellular carcinoma. Approximately 80% of newly-infected people are asymptomatic, which makes it difficult to diagnose and treat those who go on to develop chronic infection.

Newly-available drugs have revolutionized treatment. Previous treatments were poorly tolerated and had limited success. In contrast, the new treatments are easier to administer with shorter course durations and higher cure rates.

There are significant similarities between the hepatitis C epidemic and the human immunodeficiency virus (HIV) crisis of the late 1990s. Both involve global spread of underdiagnosed disease that can carry significant stigma and cause life-long illness and death. In both cases, there are new, effective products that can curb the global epidemic, held back by issues of affordability. The HIV crisis in South Africa resulted in a clash between civil society, government and the pharmaceutical industry, which led to the development of new ways of working, most notably with generic medicine manufacturers via licensing arrangements, creating a blueprint for access to medicine strategies for years to come.

However, there are also critical differences between the two epidemics that influence how pharmaceutical companies design access strategies. With HIV, the greatest disease burden is situated in lower-income countries and concentrated in sub-Saharan Africa. These countries were not viewed, in the earlier days of the epidemic, as representing market potential. In contrast, HCV is prevalent in some middle-income countries. Middle-income countries, though home to most of the world’s poor, have growing middle classes, representing economic opportunities for pharmaceutical companies. As a result, companies have an incentive to maintain exclusivity and charge higher prices in these markets. This may discourage donor, insurer and government investment in expensive new treatments, potentially slowing the adoption of new medicines.

Here we identify marketed products, product pipelines and access to medicine strategies of companies that make HCV medicines. We describe companies’ plans and activities to support greater access to HCV treatment and set out the criticisms, limitations and opportunities of these approaches. Finally, we present recommendations for companies to consider when developing access to medicine strategies for HCV-infected people.

Hepatitis C medicines
We used data from the Access to Medicine Index 2014 and other publicly-available sources such as company, patients’ organization and nongovernmental organization websites. The access to medicine index is created by the Access to Medicine Foundation, an independent initiative funded by the Bill & Melinda Gates Foundation, the Dutch Ministry of Foreign Affairs, the United Kingdom Department for International Development, and the Dutch National Postcode Lottery. The Access to Medicine Foundation engages directly with 20 of the world’s largest pharmaceutical companies, requesting data biennially on selected activities via a detailed online questionnaire. The data are used to rank the companies in...
a biennial index. This index uses a set of 95 indicators to assess companies’ comparative performance in facilitating access to medicines in poor populations. A limitation of the data is that they are largely self-reported by companies. However, the data are reviewed by an external research partner (for the 2014 index, this partner was Sustainalytics, Amsterdam, Netherlands) and the foundation’s research team, clarified with companies and verified in some areas with external data sources.

**Current treatment**

The World Health Organization (WHO) released new treatment guidelines for hepatitis C infection in April 2014.1 Given that most patients will not realize they are infected, screening is recommended for high-risk groups. In countries with high prevalence and low infection control, screening is recommended for the whole population, if resources allow this.1 However, diagnostic capacity is limited in many low- and middle-income countries.10

The size of the population requiring treatment for hepatitis C is difficult to gauge. As noted, not all of the 185 million people estimated to be infected will progress to chronic infection, and there are no conclusive predictors of disease progression.10 There is currently no vaccine against HCV.1 In higher-income countries where treatment is available, all persons diagnosed with chronic HCV infection are typically considered suitable for treatment. In countries where treatment availability is constrained, treatment is prioritized for patients in more advanced stages of the disease. Different treatment regimens are advised depending upon HCV genotype.1

Older HCV treatments comprised combination antiviral therapy with pegylated interferon (weekly injections) and ribavirin (tablet, capsules, or oral solution). Pegylated interferon, which remains on patent in most countries, was added to WHO’s essential medicines list in 2013. Ribavirin is off-patent and generic versions exist. Two companies (Merck & Co, Kenilworth, United States and Roche, Basel, Switzerland) included in the access to medicines index (Achilles, New Haven, USA) was identified as active in HCV drug development; one also manufactures ribavirin (Roche). This treatment regime is not “advancement in treatment practices”.16 Boehringer Ingehelm (Ingelheim am Rhein, Germany) ceased engagement in research and development for HCV in June 2014, in view of “multiple drug approvals expected from alternative manufacturers”.17

Of the 20 companies evaluated in the access to medicines index, six are active in HCV medicine development (AbbVie, Chicago, USA; Bristol-Myers Squibb, New York City, USA; Gilead, Foster City, USA; Johnson & Johnson, New Brunswick, USA, Merck & Co., Roche). All have products on the market and in development. In the US market Merck & Co. and Vertex recently discontinued boceprevir and telaprevir respectively, with Merck & Co. citing “advancement in treatment practices”.16 New antiviral drugs for HCV infection, known as oral directly-acting antiviral agent therapies, are now available on the market. They are more effective, safer and better-tolerated than existing therapies: 90% of people are cured.18 The therapies are orally administered and have shorter treatment courses (12–24 weeks depending on regimen and genotype), which decreases monitoring requirements.1 Five currently-marketed therapies were added to WHO’s essential medicines list in 2015 (Table 1).13

<table>
<thead>
<tr>
<th>Company</th>
<th>Brand name</th>
<th>INN</th>
<th>Class</th>
<th>Market approval</th>
<th>EML</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>Viekira Pak*</td>
<td>ombitasvir/pantaprevir/ritonavir</td>
<td>Direct acting antiviral</td>
<td>2014</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dasabuvir (combination)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AbbVie</td>
<td>Viekirax*</td>
<td>ombitasvir/pantaprevir/ritonavir</td>
<td>Direct acting antiviral</td>
<td>–</td>
<td>2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>dasabuvir</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bristol-Myers</td>
<td>Daklinza*</td>
<td>daclatasvir</td>
<td>Direct acting antiviral</td>
<td>–</td>
<td>2014</td>
</tr>
<tr>
<td>Squibb</td>
<td>Gilead</td>
<td>Sovaldi*</td>
<td>Direct acting antiviral</td>
<td>2013</td>
<td>2014</td>
</tr>
<tr>
<td></td>
<td>Harvon*</td>
<td>sofosbuvir</td>
<td>(combination)</td>
<td>2014</td>
<td>2014</td>
</tr>
<tr>
<td>Johnson &amp;</td>
<td>Olysio*</td>
<td>simeprevir</td>
<td>Direct acting antiviral</td>
<td>2013</td>
<td>2014</td>
</tr>
<tr>
<td>Johnson</td>
<td>Incivo*</td>
<td>telaprevir</td>
<td></td>
<td>2011</td>
<td>2011</td>
</tr>
<tr>
<td>Johnson &amp;</td>
<td>Victrelis*</td>
<td>boceprevir</td>
<td>Direct acting antiviral</td>
<td>2011</td>
<td>2011</td>
</tr>
<tr>
<td>Merck &amp; Co.</td>
<td>Peginteron*</td>
<td>peginterferon alfa-2b</td>
<td>Interferon</td>
<td>2001</td>
<td>2000</td>
</tr>
<tr>
<td>Roche</td>
<td>Pegasys*</td>
<td>peginterferon alfa-2a</td>
<td>Interferon</td>
<td>2002</td>
<td>2002</td>
</tr>
<tr>
<td>Roche</td>
<td>Copegus*</td>
<td>ribavirin</td>
<td>Nucleoside analogue</td>
<td>2002</td>
<td>2002</td>
</tr>
</tbody>
</table>


* Now discontinued in the US market.

Note: Only FDA and EMA drug registrations are tracked.
Kadmon and Medivir AB (Stockholm, Sweden) are also involved in marketing HCV products.18

Table 1 and Fig. 1 show, respectively, currently marketed HCV products (FDA and EMA registrations only) and an overview of products in research and development, up to date at the time of this paper’s submission. Table 1 indicates the presence of several new products on the market. Fig. 1 summarizes the progress in development of HCV medicines, with many products in phase III of clinical trials. Future competition may play an important role in enhancing affordability, contingent on the relative efficacy of competitors and how broadly companies choose to register them.

Access to medicine strategies

For the 2014 access to medicine index, companies were asked to disclose plans for making HCV products available in low- and middle-income countries. We refer to these as company access strategies. Companies shared information about equitable pricing strategies (which take affordability into account for poor populations), voluntary licensing agreements, donations of products and capacity-building initiatives. Johnson & Johnson and AbbVie disclosed no access to medicine strategies. Several new HCV products and access strategies were launched after the period of analysis ended. A summary of the access strategies identified is provided in Table 2.

Disclosure of access to medicine strategies for products that were still under development was limited across in-house and collaborative projects. This may reflect intense competition in HCV medicines. Only Gilead disclosed access strategies for products under development, having agreed licensing conditions for two products before registration.

Access strategies are in place for two newly marketed products: sofosbuvir and ledipasvir (Gilead) and were also in place for boceprevir (Merck & Co, now discontinued). Three companies are active in pricing strategies (Gilead,
Merck & Co. and Roche). Only Gilead is currently actively licensing HCV products. In late 2014, Bristol-Myers Squibb announced an intention to engage in both licensing for HCV products and tiered pricing (in which different price points are set depending on the market in which the product is sold).10

Discussion

Ensuring access to medicines is a joint responsibility of governments, companies, multilateral agencies and non-governmental organizations (NGOs). Pharmaceutical companies, being private entities, must also be able to justify their access to medicine activities to shareholders.

We have highlighted two key points of entry for pharmaceutical companies to help to address access to HCV medicines. First, affordability: the high prices attached to new medicines may be deterring donors (international or bilateral), health insurers and governments from committing sufficient funds to curbing the epidemic.11 Where drugs are paid for out-of-pocket, ensuring affordability is also critical. Second, generic manufacturers can scale up and distribute new medicines. Generating sufficient competition among generic manufacturers will place downward pressure on prices.

Affordability

Manufacturers of new HCV medicines will benefit from market exclusivity until around 2025.10 For Gilead, this monopoly has been magnified by the dominance of sofosbuvir. However, this lead will be increasingly challenged as other new entrants compete for market share. This effect is already being seen as prices for sofosbuvir in the United States are being increasingly discounted in the face of competition.20

Companies should develop, with governments, mechanisms for significant price discounting based on rigorous, well researched, transparent assessments of affordability in low- and middle-income countries, clearly taking account of the needs and abilities of payers and the presence or absence of subsidies. Separate pricing policies within countries can make sound business sense and improve access.21 In middle-income country markets with greater economic value to companies, private and public systems can be offered different brands and prices. This is known as market segmentation. Proposed strategies from Gilead for enforcing market segmentation of sofosbuvir requiring patient identification and limited dispensing were criticized for risking confidentiality and adherence.22 For poorer populations, high-volume, low-cost approaches may prove more profitable: in the United States, Gilead appears to be shifting to a higher-volume/lower-price model as competition from AbbVie intensifies.23

Gilead initially charged US$ 84 000 for a course of sofosbuvir in the United States. The lowest identified price for that treatment in a developing country was US$ 900 in Egypt.24 These prices are much higher than the drug’s production cost, which is US$ 68 to US$ 136 for a 12-week course.25 We were not able to estimate the research and development costs for this drug, and Gilead states publicly that they do not track this expenditure per product.25 High prices may be deterring bilateral, international and national funders from allocating funding at the scale required for the widespread rollout of new HCV treatments.

Generic partners

The lessons from scaling up HIV/AIDS medicines have shown that the capacity of generic medicine manufacturers to produce high-quality medicines and their knowledge of local regulatory requirements are important for manufacture, distribution and treatment. Equally important is the impact of sufficient competition from generic medicine manufacturers on prices: the average price of a first-line adult antiretroviral regimen dropped from US$ 414 per person per year in 2003 to US$ 74 in 2008.27

Licensing can also make business sense. For example, efficiencies may exist in engagement with generic manufacturers who understand local regulatory requirements well, have an existing network of contacts with developing country governments and regulators and can rapidly scale up production. Manufacturers may derive income from the application of royalties to licence agreements, for example 7% royalties were attached to the licences agreed by Gilead for sofosbuvir.28

To date, Gilead is the only manufacturer of new HCV medicines to have completed agreements with generic medicine manufacturers. The number of manufacturers11 is, arguably sufficient to engender competition and the full agreements have been publicly disclosed.29 Although the scope of the licences appears broad, they do not include key middle-income country markets with high HCV burdens, such as Brazil, China, Georgia, Mexico, Thailand and Ukraine.30 Further, it is not yet clear on what scale generic manufacturers will enter the market, nor what discounts will be realized, though NATCO, Hyderabad, India, has disclosed a price of 19 900 Indian rupees for 28 400 mg tablets in Nepal.31 On a 12-week course of treatment, this equates to approximately US$ 900. So, although Gilead’s licensing activities represent leading practice among the companies included in the access to medicine index, this approach has limitations in geographic scope and improvements in affordability are not yet clear. Bristol-Myers Squibb has also announced its intention to engage with generic medicine manufacturers, detailing the geographic scope of future licences.

Table 2. Access strategies for hepatitis C medicines, 2015

<table>
<thead>
<tr>
<th>Company</th>
<th>Brand name</th>
<th>Pricing</th>
<th>Financing</th>
<th>Licensing</th>
<th>Capacity building</th>
<th>Donations</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>Viekira Pak®</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Dakinza®</td>
<td>C</td>
<td>No</td>
<td>C</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Gilead</td>
<td>Sovaldi®</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>Olysio®</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Merck &amp; Co.</td>
<td>Pegatin®</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Roche</td>
<td>Pegasis® and Copegus®</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Notes: Yes: has a strategy; No: does not have a strategy; C: commitment only

* Including philanthropic activity.

a  With marketed product or products.

b  Including patent rights.

This table shows access strategies for hepatitis C medicines in 2015. The strategies are highlighted for each company, including pricing, financing, licensing, capacity building and donations. The table indicates whether each company has a strategy or commitment for access to hepatitis C medicines.

DOI: http://dx.doi.org/10.2471/BLT.15.157784
Regarding licensing, it is important that pharmaceutical companies agree to the most flexible terms possible, for example, minimizing royalties, not placing restrictions on supply of active pharmaceutical ingredients and allowing supply to as broad a range of countries as possible. This provides generic medicine manufacturers with the greatest potential to compete and keep prices low.

Market segmentation can broaden the geographic scope of licenses. Where patent-holders may wish to retain monopoly over higher income segments, licenses can limit markets generic manufacturers can sell to. GlaxoSmithKline and Pfizer, via their joint-venture ViV Healthcare, have tested this approach in the context of HIV medicines with the Medicines Patent Pool, segmenting public and private markets for delugovir and introducing a tiered royalty structure that enabled the inclusion of more middle-income countries.22

Plan access strategies early

Research-based companies should consider developing access strategies such as equitable pricing or voluntary licensing earlier in a product’s lifecycle (for example, in the later stages of research and development). This could reduce the time taken for products to reach those in need. In the case of voluntary licensing, agreeing terms with generic manufacturers early extends the time available for technology transfer, thereby enabling licensees to start production as soon after product registration as possible. Gilead has licensed medicines before product registration.19 To our knowledge, no other pharmaceutical company has engaged in pre-registration licensing for HCV products.

Supporting awareness and diagnosis

Since most HCV infections are initially asymptomatic, it is also important to raise sufficient awareness, reduce stigma, and build screening and diagnostic capacity to curb the epidemic. In addition to pricing and licensing, some companies disclose detailed programmes for supporting local screening and diagnostic capacity. It should be noted that such activities bring with them a significant risk of conflict of interest associated with direct contact with patient organizations or health-care professionals. Companies may seek to manage the risk of conflict through the involvement of established NGOs and/or WHO, aligning with the needs of ministries of health and integrating with existing programmes.

Merck & Co. is building screening capacity in Latin America, aimed at reducing the time taken for results to be received. Likewise, Roche, with strength in diagnostics, is engaged in building screening capacity in central Europe, the Eastern Mediterranean region and India, including awareness-raising activities.

Bristol-Myers Squibb is engaged in a project aimed at raising awareness in China, India and Japan.

Conclusion

It is clear that treatment of hepatitis C is undergoing a revolution. It is not enough however to develop effective treatment. All actors in the global health community need to ensure that these new products are available, accessible and affordable for all in need. This goal ultimately requires a multi-actor, multi-pronged approach.

The lack of access strategies disclosed for products under development is concerning, especially those in phase III clinical trials, which bear the greatest chance of market entry. It is also concerning that some companies disclosed no access strategies for either currently marketed products or products in the pipeline.

As described, pharmaceutical companies have central roles to play, particularly with regard to ensuring affordability and voluntary licensing. The available evidence provided by companies so far suggests a need for more concerted, broader engagement in access strategies.

Competing interests: None declared.

Policy & practice

Hepatitis C medicines

Sبل الحصول على أدوية التهاب الكبد الفيروسي

إن التهاب الكبد الفيروسي “في”، وهو منتشر على مستوى العالم، وتشير تقديرات عدد المصابين لهذا المرض إلى أنه يُقدر بـ 185 مليون شخص تُقيم معظمهم بالمنطقة المنخفضة ومتوسطة الدخل. وقد أثرت الفقدان الذي تم إجراه مؤخرًا في تطوير العشاق للمضادات ضد الفيروسات كعلاجات أكثر فاعلية وأمانًا مع قابلية أعلى للتحمل من جانب المريض مقارنة بالعلاجات الأخرى. هذا المرض مثير للقلق، خاصة في تلك البلدان التي تم قبولها من جانب المرضى مقارنة بالعلاجات الأخرى. يُثير هذا العلاجات فرص النجاح من ذلك الوباء، وهي تعرف بأسماء مختلفة للعلاجات التي يمكن أن تُعتبر بأنها أكثر أهمية في حال الوباء.

في هذا السياق، فإننت تندرج بعض الإجراءات التي يمكن أن تتضمنها الشركات كتبvented دورًا أكثر أهمية في هذا الوباء.

1) إعطاء الأولوية للمкалبات المقتطعة بribly الأعصار;
2) وضع إستراتيجيات للعثور على الأدوية في مراكز مبكرة من دورات الحياة للنماذج أو (3) من النصائح للجهات المصنعة لهذه الأدوية من الأدوية.

وقد يبحث في المنتجات التي تم تسويفها وقائع نقطية توفر الأدوية، وأسرتاستراتيجيات تيسير الحصول عليها لدى 20 شركة من ضمن أكبر الشركات المستحضرات الطبية في العالم، قد نست شركات منها تعمل حاليًا على تطوير أدوية علاج التهاب الكبد الفيروسي.
La hepatitis C es una epidemia global. Se estima que, en todo el mundo, hay 185 millones de personas infectadas, la mayoría de las cuales viven en países de ingresos bajos y medios. Los recientes avances en el tratamiento de la hepatitis C, como el desarrollo de antivirales, han producido terapias más efectivas, seguras y bien toleradas que los tratamientos existentes para tratar la enfermedad. Estas terapias presentan una oportunidad para poner freno a la epidemia, pero deben ser asequibles, sufrir un aumento en la producción de medicamentos genéricos y se requiere un estrechamiento en el acceso a los medicamentos para tratar la hepatitis C.

Podemos tomar medidas para inhibir la propagación de la epidemia, pero lo que se requiere es que las compañías farmacéuticas trabajen de manera coordinada para mejorar el acceso a los medicamentos. En el presente artículo, examinamos el papel de las compañías farmacéuticas en la gestión de la hepatitis C y las estrategias a seguir para facilitar el tratamiento de esta enfermedad en países con ingresos bajos y medios.
de acceso a los medicamentos de veinte de las mayores empresas farmacéuticas del mundo. Seis de estas empresas están desarrollando medicamentos para tratar la hepatitis C. AbbVie, Bristol-Myers Squibb, Gilead, Johnson & Johnson, Merck & Co. y Roche. Estas empresas emplean una gama de enfoques para apoyar el tratamiento para la hepatitis C, incluyendo las estrategias de fijación de precios, la concesión voluntaria de licencias, la creación de capacidad y las donaciones de medicamentos. Ofrecemos una visión general del compromiso de estas empresas a la hora de ofrecer acceso a los productos para tratar la hepatitis C. Sugerimos acciones que las empresas pueden llevar a cabo para tener un papel más importante a la hora de frenar esta epidemia: (i) dar prioridad a los criterios de asequibilidad; (ii) desarrollar estrategias de acceso al principio del ciclo de vida del producto; y (iii) ofrecer licencias a los fabricantes de medicamentos genéricos.

References

8. Sumner A. Global poverty, aid, and middle-income countries: the country classifications moribund or is global poverty in the process of “nationalizing”? Helsinki: UN-WIDER. 2013. p. 37.
Overview of access strategies reported by the pharmaceutical industry for hepatitis C products

The following information supplements the study published in the Bulletin of the World Health Organization on 1 November, 2015. It presents a description of access strategies for hepatitis C treatments implemented in low- and middle-income countries on a company-by-company, product-by-product basis. Broader capacity building activities (training, awareness raising, and building screening and diagnostic capacity) are presented separately for each company.

This information is drawn from data submitted by the companies in question to the 2014 Access to Medicine Index, supplemented with more recent publicly available data from company announcements and other sources (including non-governmental and patient organisation websites).

**AbbVie**

Viekira Pak® (ombitasvir/paritaprevir/ritonavir + dasabuvir), Exviera® (dasabuvir) and Viekirax® (ombitasvir/paritaprevir/ritonavir)

AbbVie’s three on-market hepatitis C treatment were launched after the period of analysis had ended for the 2014 Access to Medicine Index (from which the data for this study is drawn). No consideration of access strategies were disclosed while these drugs were still in the pipeline (during the period of analysis). No access strategies have been noted publicly since that point.

**Bristol-Myers Squibb**

Daklinza® (daclatasvir)

Bristol-Myers Squibb announced in late 2014 that it was committed to “utilising tiered pricing and licensing agreements” to facilitate access to Daklinza® (daclatasvir) in developing countries. No information is yet available about manufacturers engaged with or price points. Bristol-Myers Squibb has however confirmed the 112 countries (recently updated from 90 countries) that would potentially benefit from future licensing agreements, and the fact the licences will be royalty-free. These are broadly similar to Gilead’s access provisions for Sovaldi® (sofosbuvir), with similar limitations in the exclusion of several high-burden middle-income countries. Bristol-Myers Squibb has additionally excluded Egypt, a high-burden country for hepatitis C. With respect to its planned pricing arrangements, the company notes that it will take into account “countries’ economic development and burden of disease, as well as the commitment of the government to holistically address hepatitis C, including treatment and care.” It commits to applying the lowest pricing tier it sets to all low-income and Least Developed Countries.

**Broader capacity building activities**

Under the umbrella programme ‘Delivering Hope’, Bristol-Myers Squibb provides grants prioritised for the training of healthcare workers, awareness raising and education around hepatitis B and C in China and India. This has involved 61 grants totalling approximately US$18.2 million.
Gilead

Sovaldi® (sofosbuvir) and Harvoni® (sofosbuvir/ledipasvir)
Gilead initially set a price point of US$84,000 for a course of treatment with Sovaldi® (sofosbuvir) in the USA. A US$900 price tag for a course of treatment (US$300 per bottle) was first noted in Egypt, and Gilead states that this price also applies in the 101 countries included in the licensing agreements described below. Gilead also reports a US$400 (per bottle) price tag for Harvoni® (sofosbuvir/ledipasvir) for the same country scope.

Gilead has not disclosed details about how or whether affordability (for target populations) was taken into account in reaching these prices. These discounted prices have been noted by researchers at the University of Liverpool as being significantly above the drug’s cost of production (US$68-US$136 for a 12-week course of sofosbuvir.)

Gilead has agreed licensing terms for Sovaldi® (sofosbuvir), both on its own and in combination with ledipasvir and pipeline product GS-5816 (velpatasvir). Agreements have been reached with eleven Indian manufacturers for supply to 101 developing countries. Agreeing licensing terms outside of the HIV/AIDS therapeutic area has been noted as pioneering. Criticism centres on the exclusion of certain middle-income country markets that shoulder a significant hepatitis C burden (e.g., Brazil, China, Ukraine) and the potential negative effects of anti-diversionary policies intended to secure market segments. In addition, a lack of clarity is noted around whether generic partners are permitted to supply to countries where patent applications have been rejected or are pending.

Gilead is the only company analysed to have engaged in concrete access strategies for products that were still in the pipeline at point of licensing (two products, ledipasvir and GS-5816 (velpatasvir). Ledipasvir has since been approved (in combination with sofosbuvir) by both the FDA and EMA, and is marketed as Harvoni®.

Johnson & Johnson

Olysio® (simeprevir), Incivo®/Incivek® (telaprevir)
No data was provided concerning strategies to make Olysio® (simeprevir) and Incivo®/Incivek® (telaprevir) more accessible in Index countries. Vertex, responsible for marketing Incivek® (telaprevir) in the US, has indicated intention to withdraw from that market. No access strategies were disclosed for hepatitis C products still under development. No access strategies have been noted publicly since that point.

Merck & Co.

PegIntron® (peginterferon alfa-2b)
Merck & Co. disclosed information about the inter-country equitable pricing strategy it has in place for its interferon treatment PegIntron® (peginterferon alfa-2b). Merck & Co. has set a single access price of US$40 per vial to public sector customers in low-income and Least Developed Countries, as defined by the World Bank and the United Nations.

Merck & Co. provides microcredit in India with the aim of increasing access to PegIntron® (peginterferon alfa-2b). Through its ‘Programme Sambhav’, it offers zero-interest no-collateral loans in 11 cities across four states in India. In 2013, the programme involved 30% of treated patients in the state of Punjab. While this represents a novel approach to improving patient access to treatment, microfinance has received criticism, particularly in the context of healthcare.

Broader capacity building activities
Merck & Co. partners with pharmaceutical company Abbott in Latin America with the aim of
Access to Medicine Foundation

reducing the time taken for diagnostic test results to be received. The collaboration initially includes Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Panama, Peru and Venezuela.

Merck & Co. provided a three-year grant of US$650,000 to a partner organisation, aimed at improving access to information about hepatitis C and to build awareness of the disease in at-risk groups in Vietnam. Merck & Co. also provided a grant of US$70,000 in Thailand to provide educational information at blood centres.

Roche

Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin)
Roche has agreed both intra-country and inter-country equitable pricing strategies for Pegasys® (peginterferon alfa-2a). Roche segments markets using different strategies: for example, in Egypt, it applies a second-brand strategy and the product is packaged locally.

Roche has entered into agreements with country governments in Cameroon, Cote d'Ivoire, Mauritania, Indonesia and Vietnam, for providing Pegasys® (peginterferon alfa-2a) either free of charge or at a discount, and for providing Copegus® (ribavirin) free of charge for specific groups of patients who lack health insurance or pay out of pocket.

Broader capacity building activities
Roche has supported various national programmes for hepatitis C management. In Brazil, this involved provision of testing facilities, free tests and educational campaigns to increase awareness of the disease and access to diagnosis. In Cameroon, it engages in awareness and screening campaigns (with a target of reaching 10,000 patients per year) and a patient registry is planned.

Roche supports a patient registry in Cote d'Ivoire, development of screening and disease management policy in Ghana, training activities in Mauritania, education/awareness-raising in Indonesia and the provision of free testing and awareness raising activities in Vietnam. Roche also supports the building of test infrastructure and training activities in Armenia, Georgia, India, Iraq, Kyrgyzstan, Uzbekistan, and the West Bank and Gaza. However, information was not available regarding the scale and scope of these activities.
About the 2014 Access to Medicine Index

This findings in this report are based on the analysis of data submitted by pharmaceutical companies to the 2014 Access to Medicine Index. The Access to Medicine Index independently ranks 20 of the world’s largest pharmaceutical companies by revenue on their efforts to improve access to medicine for people living in developing countries. Funded by the Bill & Melinda Gates Foundation and the UK and Dutch governments, the Index has been published every two years since 2008.

By publicly recognising companies’ access-related policies and practices, the Index raises awareness of relevant issues within pharmaceutical companies and provides them with a transparent means of assessing, monitoring and improving their own performances as well as their public and investment profiles. Consistent iterations of the Index highlight industry trends and provide a basis for multi-stakeholder dialogue and solution building.

The Access to Medicine Index uses a weighted analytical framework to consistently capture and compare data from the top 20 research-based pharmaceutical companies across a set of countries, diseases and product types. For each successive Index, the Index research team works with independent representatives of relevant stakeholder groups to refine this framework, to confirm the robustness and usefulness of our analysis, and align it with developments in the access-to-medicine landscape and pharmaceutical industry. The framework is constructed along seven areas of focus, which cover the range of company business activities that experts consider most relevant to access to medicine. Within each area, the Index assesses four aspects of company action: commitment, transparency, performance and innovation.

Analysis scopes for the 2014 Access to Medicine Index

Company scope

The companies covered by the Index account for more than 50% of the global pharmaceutical market.
### Disease scope

**Figure 4: DALYs of diseases in the 2014 Access to Medicine Index**

Communicable diseases
- Lower respiratory infections
- Diarrhoeal diseases
- Unipolar depressive disorder
- Ischaemic heart disease
- HIV/AIDS
- Cerebrovascular disease
- Prematurity and low birth weight
- Birth asphyxia and birth trauma
- Neonatal infections and other conditions
- Tuberculosis
- Malaria

Non-communicable diseases
- Chronic obstructive pulmonary disorder [COPD]
- Diabetes mellitus
- Schizophrenia
- Asthma
- Osteoarthritis
- Measles
- Bipolar affective disorder
- Cirrhosis of the liver
- Meningitis
- Pertussis
- Nephritis and nephrosis
- Epilepsy
- Abortion
- Maternal sepsis
- Lymphatic filariasis
- Tetanus
- Maternal haemorrhage
- Soil transmitted helminthiasis
- Chlamydia
- Obstructed labour
- Leishmaniasis
- Hypertensive disorders of pregnancy
- Food-borne trematodiases
- Schistosomiasis
- Trypanosomiasis
- Rabies
- Trachoma
- Dengue
- Cysticercosis
- Chagas disease
- Onchocerciasis
- Leprosy
- Echinococcosis
- Buruli Ulcer
- Yaws
- Dracunculiasis
- Contraceptive methods

Neglected tropical diseases
- Hepatitis C

Maternal & neonatal health conditions
- Prematurity and low birth weight
- Birth asphyxia and birth trauma
- Neonatal infections and other conditions
- Tuberculosis
- Malaria

Diseases/conditions considered for this analysis
- Communicable diseases
- Non-communicable diseases
- Neglected tropical diseases
- Maternal & neonatal health conditions
- Diseases/conditions considered for this analysis

DALYs total per 100,000
## Country scope

Table 7: List of countries included in the 2014 Access to Medicine Index – 106 countries

<table>
<thead>
<tr>
<th>Country</th>
<th>Classification</th>
<th>Country</th>
<th>Classification</th>
<th>Country</th>
<th>Classification</th>
<th>Country</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>East Asia &amp; Pacific</td>
<td></td>
<td>Suriname</td>
<td>MHDC</td>
<td>Liberia</td>
<td>LIC</td>
<td>Countries removed since</td>
<td></td>
</tr>
<tr>
<td>Cambodia</td>
<td>LIC*</td>
<td>Venezuela, RB</td>
<td>HiHDI</td>
<td>Madagascar</td>
<td>LIC*</td>
<td>2012 Index</td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>MHDC</td>
<td></td>
<td></td>
<td>Malawi</td>
<td>LIC*</td>
<td>Algeria</td>
<td></td>
</tr>
<tr>
<td>Fiji</td>
<td>MHDC</td>
<td></td>
<td></td>
<td>Mali</td>
<td>LIC*</td>
<td>Marshall Islands</td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>LMIC</td>
<td>Djibouti</td>
<td>LMIC*</td>
<td>Mauritania</td>
<td>LMIC*</td>
<td>UMIC</td>
<td></td>
</tr>
<tr>
<td>Kiribati</td>
<td>LMIC</td>
<td>Egypt, Arab Rep.</td>
<td>LMIC</td>
<td>Mozambique</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Korea, Dem. Rep.</td>
<td>LIC</td>
<td>Iraq</td>
<td>MHDC</td>
<td>Namibia</td>
<td>MHDC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lao PDR</td>
<td>LMIC*</td>
<td>Jordan</td>
<td>MHDC</td>
<td>Niger</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micronesia, Fed. Sts.</td>
<td>LMIC</td>
<td>Morocco</td>
<td>LMIC</td>
<td>Nigeria</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mongolia</td>
<td>LMIC</td>
<td>Syrian Arab Rep.</td>
<td>LMIC</td>
<td>Rwanda</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myanmar</td>
<td>LIC*</td>
<td>West Bank and Gaza</td>
<td>LMIC</td>
<td>São Tomé and Principe</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>LMIC</td>
<td>Yemen, Rep.</td>
<td>LMIC</td>
<td>Senegal</td>
<td>LMIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philippines</td>
<td>LMIC</td>
<td></td>
<td></td>
<td>Sierra Leone</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Samoa</td>
<td>LMIC*</td>
<td></td>
<td></td>
<td>Somalia</td>
<td>LIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>LMIC*</td>
<td>Afghanistan</td>
<td>LIC</td>
<td>South Africa</td>
<td>MHDC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand</td>
<td>MHDC</td>
<td>Bangladesh</td>
<td>LIC*</td>
<td>South Sudan</td>
<td>LIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timor-Leste</td>
<td>LMC</td>
<td>Bhutan</td>
<td>LMIC</td>
<td>Sudan</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tonga</td>
<td>MHDC</td>
<td>India</td>
<td>LMIC</td>
<td>Swaziland</td>
<td>LMIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuvalu</td>
<td>LDC</td>
<td>Maldives</td>
<td>MHDC</td>
<td>Tanzania</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vanuatu</td>
<td>LMIC*</td>
<td>Nepal</td>
<td>LIC*</td>
<td>Togo</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vietnam</td>
<td>LMIC</td>
<td>Pakistan</td>
<td>LMIC</td>
<td>Uganda</td>
<td>LIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sri Lanka</td>
<td>LMIC</td>
<td>Zambia</td>
<td>LMIC*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Zimbabwe</td>
<td>LIC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Europe &amp; Central Asia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Armenia</td>
<td>LMIC</td>
<td>Angola</td>
<td>LHDC*</td>
<td>LIC: Low-income Country</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Georgia</td>
<td>LMIC</td>
<td>Benin</td>
<td>LIC*</td>
<td>World Bank income classification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kosovo</td>
<td>LMIC</td>
<td>Botswana</td>
<td>MHDC</td>
<td>LMIC: Lower-middle-income Country</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kyrgyz Rep.</td>
<td>LIC</td>
<td>Burkina Faso</td>
<td>LIC*</td>
<td>World Bank income classification</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moldova</td>
<td>LMIC</td>
<td>Burundi</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tajikistan</td>
<td>LIC</td>
<td>Cameroon</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Turkmenistan</td>
<td>MHDC</td>
<td>Cape Verde</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ukraine</td>
<td>LMIC</td>
<td>Central African Rep.</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>LMIC</td>
<td>Chad</td>
<td>LIC*</td>
<td>Least Developed Country</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comoros</td>
<td>LIC</td>
<td>UN Human Development Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Congo, Dem. Rep.</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Congo, Rep.</td>
<td>LMIC</td>
<td>UN Human Development Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Côte d'Ivoire</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Equatorial Guinea</td>
<td>MHDC</td>
<td>UN Human Development Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Eritrea</td>
<td>LIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ethiopia</td>
<td>LIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gabon</td>
<td>MHDC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gambia, The</td>
<td>LIC*</td>
<td>HiHDI: High Human Development Country with high inequality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ghana</td>
<td>LMIC</td>
<td>UN Inequality-Adjusted Human Development Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Guinea</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Guinea-Bissau</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latin America &amp; Caribbean</td>
<td></td>
<td>Kenya</td>
<td>LIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belize</td>
<td>MHDC</td>
<td>Lesotho</td>
<td>LMIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bolivia</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brazil</td>
<td>HIHDI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colombia</td>
<td>HIHDI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dominican Rep.</td>
<td>MHDC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ecuador</td>
<td>HIHDI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>El Salvador</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guatemala</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guyana</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haiti</td>
<td>LIC*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Honduras</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicaragua</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paraguay</td>
<td>LMIC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

* LDC with WTO membership

5 Countries newly included countries in the 2014 Index scope

2 Countries removed from the index scope
**Product scope**

The product type scope for Index 2014 remains necessarily broad to capture the wide-ranging product types available to support prevention, diagnosis and treatment of Index Diseases in the Index countries.

It draws closely from the definitions provided by the G-Finder 2012 Neglected Disease Research and Development: A Five Year Review, and remains unchanged from the 2012 and 2010 Indices.

**Medicines**

All innovative and adaptive medicines, branded generics and generic medicines used to directly treat the target pathogen or disease process, regardless of formulation, are included. Medicines used only for symptomatic relief are not included.

**Microbicides**
These include topical microbicides intended to prevent HIV.

**Therapeutic vaccines**
This covers vaccines intended to treat infection.

**Preventive vaccines**
This covers vaccines intended to prevent infection.

**Diagnostics**
Diagnostic tests designed for use in resource-limited settings (cheaper, faster, more reliable, greater ease of use in the field) are included.

**Vector control products**
These include pesticides, biological control compounds and vaccines targeting animal reservoirs. Only chemical pesticides intended for global public health use and which specifically aim to inhibit and kill vectors that transmit diseases relevant to the Index are included. Likewise, only biological control interventions that specifically aim to kill or control vectors that transmit Index-relevant diseases are included. Only veterinary vaccines specifically designed to prevent animal-to-human transmission of diseases covered by the Index are included.

**Platform technologies**
Only those products directed specifically at meeting the needs of countries covered by the Index are included. These comprise general diagnostic platforms, adjuvants and immunomodulators, and delivery technologies and devices.
Access to Medicine Foundation
Scheepmakersdijk 5a
NL-2011 AS Haarlem
The Netherlands

On behalf of the Access to Medicine Foundation, please contact
Danny Edwards, Research Programme Manager
E dedwards@atmindex.org
T +31 (0)23 53 39 187
W www.accesstomedicineindex.org

Funders
The Access to Medicine Foundation is independently funded by the
Bill & Melinda Gates Foundation, the UK Department for International
Development (DFID), and the Dutch Ministry of Foreign Affairs.